This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Prostate Cancer
  • /
  • PBX3 is a putative biomarker of aggressive Prostat...
Journal

PBX3 is a putative biomarker of aggressive Prostate Cancer.

Read time: 1 mins
Published:14th Oct 2016
Author: Ramberg H, Grytli HH, Nygård S, Wang W, Ögren O, Zhao S et al.
Availability: Free full text
Ref.:Int J Cancer. 2016 Oct 15;139(8):1810-20.
DOI:10.1002/ijc.30220.
PBX3 is a putative biomarker of aggressive prostate cancer


There is a great need to identify new and better prognostic and predictive biomarkers to stratify prostate cancer patients for optimal treatment. The aims of this study were to characterize the expression profile of pre-B cell leukemia homeobox (PBX) transcription factors in prostate cancer with an emphasis on investigating whether PBX3 harbours any prognostic value. The expression profile of PBX3 and PBX1 in prostate tissue was determined by immunohistochemical and immunoblot analysis. Furthermore, the expression of PBX3 transcript variants was analyzed by RT-PCR, NanoString Technologies®, and by analyzing RNA sequence data. The potential of PBX3 to predict prognosis, either at mRNA or protein level, was studied in four independent cohorts. PBX3 was mainly expressed in the nucleus of normal prostate basal cells, while it showed cytosolic expression in prostatic intraepithelial neoplasia and cancer cells. We detected four PBX3 transcript variants in prostate tissue. Competing risk regression analysis revealed that high PBX3 expression was associated with slower progression to castration resistant prostate cancer (sub-hazard ratio (SHR) 0.18, 95% CI: 0.081-0.42, p-value<0.001). PBX3 expression had a high predictive accuracy (area under the curve (AUC) =0.82) when combined with Gleason score and age. Patients undergoing radical prostatectomy, with high levels of PBX3 mRNA, had improved prostate cancer specific survival compared to patients expressing low levels (SHR 0.21, 95% CI: 0.46-0.93, p-value<0.001, and AUC=0.75). Our findings strongly indicate that PBX3 has potential as a biomarker, both as part of a larger gene panel and as an immunohistochemical marker, for aggressive prostate cancer.


Read abstract on library site    Access full article